MICHAEL MOLESEVICH: Open Payments
NPI 1740697564 · SELINSGROVE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$633 in 35 payments from 13 companies in 2025. Trend: 2023 $450 · 2024 $570 · 2025 $633
Food & beverage: $633
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $168 |
| Novo Nordisk Inc | 6 | $110 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $55 |
| Lilly USA, LLC | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| PFIZER INC. | 2 | $31 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| Exact Sciences Corporation | 1 | $29 |
| CeQur Corporation | 1 | $28 |
Products named: Ozempic, UBRELVY, QULIPTA, Kerendia, VRAYLAR, VOQUEZNA, Wegovy, CAPLYTA.
Industry payments across PA — which companies pay providers there.
